« Previous
Next »
Seminars in Oncology
Volume 36
, Pages
S55-S68
, August 2009
The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors
-
Proposal for a pilot phase II single-arm, open-label clinical trial of capecitabine and liposomal cytarabine for the treatment of newly diagnosed neoplastic meningitis with or without central nervous
Proposal for a pilot phase II single-arm, open-label clinical trial of capecitabine and liposomal cytarabine for the treatment of newly diagnosed neoplastic meningitis with or without central nervous system metastases in patients with breast cancer.
-
(A) Proposal for an intra-cerebrospinal fluid (CSF) prophylaxis trial in patients with brain metastases from breast cancer. Stratification for: CSF cytology (positive v negative v uncertain); tumor si(A) Proposal for an intra-cerebrospinal fluid (CSF) prophylaxis trial in patients with brain metastases from breast cancer. Stratification for: CSF cytology (positive v negative v uncertain); tumor site (posterior fossa v cerebral hemispheres); surgical resection (yes v no); and vertebral metastases (yes v no). (B) Proposal for a CSF prophylaxis trial in patients with brain metastases from breast cancer. CR, complete response; PR, partial response; MRI, magnetic resonance imaging; RPA, recursive partitioning analysis (used for prognostic classification); S, surgery; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy.
-
Proposal for a pilot clinical trial assessing whether chemoprophylaxis reduces the incidence of neoplastic meningitis in patients with posterior fossa central nervous system metastases who undergo surProposal for a pilot clinical trial assessing whether chemoprophylaxis reduces the incidence of neoplastic meningitis in patients with posterior fossa central nervous system metastases who undergo surgical resection. CSF, cerebrospinal fluid; EVD, extra vascular drainage; IHC, immunohistochemistry; MRI, magnetic resonance imaging.
STATEMENT OF CONFLICT OF INTEREST: The authors have nothing to disclose.
PII: S0093-7754(09)00097-9
doi: 10.1053/j.seminoncol.2009.05.007
© 2009 Elsevier Inc. All rights reserved.
« Previous
Next »
Seminars in Oncology
Volume 36
, Pages
S55-S68
, August 2009
